Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.

Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substr...

Descripción completa

Detalles Bibliográficos
Autor principal: Meyer, U. A.
Formato: Texto
Lenguaje:English
Publicado: Yale Journal of Biology and Medicine 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589004/
https://www.ncbi.nlm.nih.gov/pubmed/9165689
_version_ 1782161035282612224
author Meyer, U. A.
author_facet Meyer, U. A.
author_sort Meyer, U. A.
collection PubMed
description Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substrates explain some of the observed interactions with carbamazepin, diazepam, phenytoin and theophylline and of the impact of the CYP2C19 (mephenytoin) genetic polymorphism. Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies.
format Text
id pubmed-2589004
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Yale Journal of Biology and Medicine
record_format MEDLINE/PubMed
spelling pubmed-25890042008-12-01 Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Meyer, U. A. Yale J Biol Med Research Article Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substrates explain some of the observed interactions with carbamazepin, diazepam, phenytoin and theophylline and of the impact of the CYP2C19 (mephenytoin) genetic polymorphism. Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies. Yale Journal of Biology and Medicine 1996 /pmc/articles/PMC2589004/ /pubmed/9165689 Text en
spellingShingle Research Article
Meyer, U. A.
Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title_full Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title_fullStr Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title_full_unstemmed Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title_short Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
title_sort interaction of proton pump inhibitors with cytochromes p450: consequences for drug interactions.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589004/
https://www.ncbi.nlm.nih.gov/pubmed/9165689
work_keys_str_mv AT meyerua interactionofprotonpumpinhibitorswithcytochromesp450consequencesfordruginteractions

Ejemplares similares